Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126462791 | 12646279 | 1 | I | 20160802 | 20160812 | 20160812 | EXP | TR-009507513-1608TUR005013 | MERCK | 0.00 | Y | 0.00000 | 20160812 | OT | TR | TR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126462791 | 12646279 | 1 | PS | MIRTAZAPINE. | MIRTAZAPINE | 1 | Transplacental | UNK | U | 20415 | TABLET | ||||||||
| 126462791 | 12646279 | 2 | SS | ESCITALOPRAM | ESCITALOPRAM OXALATE | 1 | Transplacental | UNK | U | 0 | |||||||||
| 126462791 | 12646279 | 3 | SS | BUTYLSCOPOLAMINE BROMIDE | BUTYLSCOPOLAMINE BROMIDE | 1 | Transplacental | UNK | U | 0 | |||||||||
| 126462791 | 12646279 | 4 | SS | MEDAZEPAM | MEDAZEPAM | 1 | Transplacental | UNK | U | 0 |
Indications of drugs used
| no results found |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126462791 | 12646279 | CA |
| 126462791 | 12646279 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126462791 | 12646279 | Foetal exposure during pregnancy | |
| 126462791 | 12646279 | Limb reduction defect |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |